FDA to investigate Lilly's handling of Zyprexa data

The FDA has opened an inquiry to determine if Eli Lilly manipulated the data it submitted for Zyprexa, a controversial antipsychotic that has been linked to rapid weight gain and diabetes. The agency has raised questions about a document Lilly generated in 2000 that outlined how patients taking Zyprexa in a clinical trial were three and a half times more likely to develop high blood sugar than patients in the control wing. But that document never made it to the FDA. Regulators instead received a report several months later that said that there was virtually no difference in blood sugar levels. A Lilly document said that the earlier--undelivered--report was checked for errors and that the later report was accurate. Zyprexa earns $4 billion a year, though U.S. sales have fallen dramatically as the controversy over the drug has developed.

- read the New York Times report on the FDA's inquiry

Related Articles:
Eli Lilly responds to Zyprexa claims. Report
Lilly to pay $500 million to settle Zyprexa diabetes claims. Report
Lilly accused of promoting off-label Zyprexa use. Report
NIH doctors slam Lilly's marketing tactics. Report

Suggested Articles

Monte Rosa Therapeutics raised $96 million to ramp up its pipeline of "molecular glue"

Silverback Therapeutics reeled in $85 million to advance its lead antibody-drug conjugate through the clinic and develop its earlier-stage pipeline.

The reported requirements suggest a company is unlikely to have the data needed to support an EUA before the election in six weeks.